Catalent (NYSE:CTLT) Shares Down 8.8%


Share on StockTwits

Catalent, Inc. (NYSE:CTLT)’s stock price was down 8.8% on Tuesday . The company traded as low as $101.86 and last traded at $101.94. Approximately 54,452 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 1,026,055 shares. The stock had previously closed at $111.78.

Several research firms have issued reports on CTLT. JPMorgan Chase & Co. boosted their price objective on Catalent from $110.00 to $130.00 and gave the stock an “overweight” rating in a report on Friday, January 8th. Argus boosted their price target on shares of Catalent from $130.00 to $140.00 and gave the company a “buy” rating in a report on Tuesday, March 2nd. They noted that the move was a valuation call. UBS Group upped their price target on shares of Catalent from $115.00 to $135.00 and gave the company a “buy” rating in a research report on Wednesday, February 3rd. Royal Bank of Canada lifted their price objective on shares of Catalent from $125.00 to $137.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 3rd. Finally, Zacks Investment Research lowered Catalent from a “buy” rating to a “hold” rating in a report on Monday. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $125.67.

The business’s 50-day simple moving average is $108.38 and its 200-day simple moving average is $106.35. The company has a market cap of $17.65 billion, a PE ratio of 65.68, a P/E/G ratio of 2.68 and a beta of 1.50. The company has a current ratio of 2.56, a quick ratio of 2.14 and a debt-to-equity ratio of 0.97.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Tuesday, May 4th. The company reported $0.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.09. The business had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $994.28 million. Catalent had a net margin of 9.25% and a return on equity of 14.20%. Catalent’s revenue for the quarter was up 38.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.50 earnings per share. On average, research analysts predict that Catalent, Inc. will post 2.35 earnings per share for the current fiscal year.

In other Catalent news, CFO Wetteny Joseph sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 16th. The shares were sold at an average price of $124.54, for a total value of $622,700.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John R. Chiminski sold 42,220 shares of the stock in a transaction on Thursday, March 18th. The stock was sold at an average price of $105.16, for a total transaction of $4,439,855.20. The disclosure for this sale can be found here. Insiders have sold a total of 74,871 shares of company stock valued at $7,997,007 over the last ninety days. Company insiders own 1.00% of the company’s stock.

A number of institutional investors have recently bought and sold shares of CTLT. BlackRock Inc. lifted its position in shares of Catalent by 0.5% in the fourth quarter. BlackRock Inc. now owns 13,286,853 shares of the company’s stock worth $1,382,764,000 after buying an additional 68,225 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Catalent by 0.6% in the 4th quarter. JPMorgan Chase & Co. now owns 5,332,447 shares of the company’s stock worth $554,950,000 after purchasing an additional 31,411 shares during the last quarter. Nuveen Asset Management LLC boosted its position in Catalent by 0.8% during the fourth quarter. Nuveen Asset Management LLC now owns 1,485,969 shares of the company’s stock worth $154,645,000 after purchasing an additional 12,130 shares during the period. Norges Bank acquired a new position in Catalent during the fourth quarter valued at approximately $149,074,000. Finally, Bank of New York Mellon Corp raised its position in shares of Catalent by 5.0% in the fourth quarter. Bank of New York Mellon Corp now owns 1,362,467 shares of the company’s stock valued at $141,793,000 after purchasing an additional 64,787 shares during the period. 97.84% of the stock is currently owned by hedge funds and other institutional investors.

About Catalent (NYSE:CTLT)

Catalent, Inc, together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.

Featured Story: What is the price-to-earnings growth (PEG) ratio?

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.